ORIC
Oric Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.72
+3.00%Oct 19, 2026, 12:00 UTC
Oric Pharmaceuticals, Inc. announced that it will host a conference call and webcast on October 23, 2026, to review enozertinib data presented at the Oric Pharmaceuticals, Inc..
Source:Oct 5, 2026, 20:01 UTC
ORIC Pharmaceuticals announced an agreement with Cancer Research UK under which Cancer Research UK will fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259, a CIP2A-targeted therapy, while ORIC retains an exclusive option to reacquire rights after Phase 1/2 data.
Source:Oct 2, 2026, 20:30 UTC
ORIC Pharmaceuticals granted 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees on October 1, 2026.
Source:Aug 7, 2026, 20:30 UTC
ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees on August 3, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).
Source:Jul 14, 2026, 20:05 UTC
ORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 trial of rinzimetostat in combination with darolutamide for mCRPC patients previously treated with abiraterone.